Biogen Reports Mixed Q4 Results and Lowers 2025 Outlook

The biotech firm's earnings beat expectations, but challenges in core product sales and a cautious profit forecast weigh on investor sentiment.

Biogen's Q4 revenue rose 3% year-over-year to $2.46 billion, exceeding analyst expectations of $2.40 billion.
Adjusted earnings per share for the quarter reached $3.44, surpassing the $3.35 forecast by analysts.
Alzheimer's drug Leqembi generated $87 million in Q4 revenue, outperforming projections, but its U.S. rollout faced logistical challenges.
Biogen's 2025 profit outlook of $15.25 to $16.25 per share fell short of Wall Street's $16.34 estimate, with expected mid-single-digit revenue declines due to competition in the multiple sclerosis market.
Despite cost-cutting efforts and new product launches, Biogen's stock remains under pressure, reflecting investor concerns over long-term growth prospects.